Search Result

Results for "

bone inducible factors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HIF/HIF Prolyl-Hydroxylase (2) Akt (2) Apoptosis (2) Autophagy (3) c-Fms (3) Endogenous Metabolite (4) Interleukin Related (2) NF-κB (2) NO Synthase (4) p38 MAPK (1) RANKL/RANK (1) Reactive Oxygen Species (ROS) (3) Reference Standards (3) Smo (1) TGF-beta/Smad (2) TGF-β Receptor (1) TNF Receptor (2)
By Research Areas:	Cancer (7) Cardiovascular Disease (4) Inflammation/Immunology (6) Metabolic Disease (4)
Oligonucleotides:	Emulsifiers (1)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: HIF/HIF Prolyl-Hydroxylase Salt-inducible Kinase (SIK) RUNX Itk AIM2

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-158203

BMP agonist 2	TGF-β Receptor	Others
BMP agonist 2 (derivative I-9) is a potent bone-inducing cytokine. BMP agonist 2 promotes bone tissue production by increasing the proportion and activity of osteoblasts. BMP agonist 2 promotes osteoblast proliferation and differentiation through the BMP2-ATF4 signaling axis, in which ATF4 is a transcription factor closely related to osteoblast differentiation and bone formation. BMP agonist 2 can be used in the study of senile osteoporosis (SOP) .

HY-16268A

Kartogenin sodium Maximum Cited Publications 26 Publications Verification KGN sodium	TGF-beta/Smad	Inflammation/Immunology
Kartogenin (KGN) sodium is an inducer of chondrogenic tissue formation (EC₅₀: 100 nM). Kartogenin sodium induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin sodium also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin sodium is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin sodium promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .

HY-16268

Kartogenin Maximum Cited Publications 26 Publications Verification KGN	TGF-beta/Smad	Inflammation/Immunology
Kartogenin (KGN) is an inducer of chondrogenic tissue formation (EC₅₀: 100 nM). Kartogenin induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .

HY-112499

Menaquinone-7 2 Publications Verification Vitamin K2-7; Vitamin K2(35); Vitamin MK-7	Others	Cardiovascular Disease
Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .

HY-112499R

Menaquinone-7 (Standard) 2 Publications Verification Vitamin K2-7(Standard); Vitamin K2(35)(Standard); Vitamin MK-7 (Standard)	Endogenous Metabolite Reference Standards	Cardiovascular Disease
Menaquinone-7 (Standard) is the analytical standard of Menaquinone-7. This product is intended for research and analytical applications. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .

HY-12316

20(S)-Hydroxycholesterol 2 Publications Verification 20α-Hydroxycholesterol	Smo Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Cancer
20(S)-Hydroxycholesterol (20α-Hydroxycholesterol) is an allosteric activator that selectively targets the Smoothened (Smo) of the Hedgehog pathway with an EC₅₀ of ~30 μM (Hedgehog). 20(S)-Hydroxycholesterol binds to the extracellular cysteine-rich domain (CRD) of Smo in a stereoselective manner, activating downstream Gli transcription factors (without inducing transcription of receptor genes in the Wnt pathway). 20(S)-Hydroxycholesterol enhances osteogenic differentiation of bone marrow stromal cells and synergistically activates the Raf/MEK/ERK pathway with Simvastatin (HY-17502) to promote bone regeneration. 20(S)-Hydroxycholesterol can be used to study the mechanisms of developmental biology, oncology, bone, and angiogenesis .

HY-125393

Leustroducsin A	c-Fms	Cancer
Leustroducsin A is a *colony-stimulating factor* (CSF)** inducer. Leustroducsin A induces production of CSF by bone marrowstromal cells .

HY-125377

Leustroducsin C	c-Fms	Cancer
Leustroducsin C is a *colony-stimulating factor* (CSF)** inducer. Leustroducsin C induces production of CSF by bone marrowstromal cells .

HY-125086

Leustroducsin B LSN-B	c-Fms	Cardiovascular Disease
Leustroducsin B is a *colony-stimulating factor* (CSF)** inducer. Leustroducsin B induces CSF production in bone marrow stromal cells .

HY-162866

CXM102	Autophagy	Metabolic Disease
CXM102 is an autophagy activator. CXM102 can induce autophagy in aged BMSCs, leading to the rejuvenation of BMSCs and preferential differentiation into osteoblasts. CXM102 promotes the nuclear translocation of transcription factor EB (TFEB) and the formation of osteoblasts. CXM102 can stimulate bone synthesis metabolism in middle-aged male mice, reduce bone marrow adipocytes, delay bone loss, lower serum inflammation levels, decrease organ fibrosis, and extend the lifespan of the mice .

HY-169703

SPA0355	RANKL/RANK p38 MAPK Akt NF-κB	Inflammation/Immunology
SPA0355 is a thiourea derivative that has antioxidant and anti-inflammatory properties. SPA0355 inhibits the RANKL (receptor activator of nuclear factor κB ligand) induced osteoclast formation in primary bone marrow-derived macrophages. SPA0355 also suppresses the activation of the MAPKs, Akt, and NF-κB pathways. Additionally, SPA0355 promotes osteoblast differentiation, increases alkaline phosphatase activity, and enhances mineral nodule formation. SPA0355 can protect ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it useful for studying postmenopausal osteoporosis .

HY-W016409

Ethyl 3,4-dihydroxybenzoate 1 Publications Verification Protocatechuic acid ethyl ester	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) NO Synthase Autophagy Apoptosis	Metabolic Disease Cancer
Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of *hypoxia-inducible* factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α** by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

HY-128754

Monoolein 1 Publications Verification	Endogenous Metabolite Interleukin Related TNF Receptor NO Synthase	Inflammation/Immunology
Monoolein is a biocompatible lipid molecule that can be used as a carrier for bone repair. Monoolein exhibits anti-inflammatory activity by inhibiting the immune response induced by LPS (HY-D1056). It exerts its anti-inflammatory effects by reducing the production of immune response factors such as IL-12 p40, IL-6, and TNF-α, and inhibiting the generation of NO. Monoolein can be used in drug delivery and research in the field of inflammatory diseases .

HY-128754R

Monoolein (Standard)	Reference Standards Endogenous Metabolite Interleukin Related TNF Receptor NO Synthase	Inflammation/Immunology
Monoolein is a biocompatible lipid molecule that can be used as a carrier for bone repair. Monoolein exhibits anti-inflammatory activity by inhibiting the immune response induced by LPS (HY-D1056). It exerts its anti-inflammatory effects by reducing the production of immune response factors such as IL-12 p40, IL-6, and TNF-α, and inhibiting the generation of NO. Monoolein can be used in drug delivery and research in the field of inflammatory diseases .

HY-N6588

3,4,5-Tricaffeoylquinic acid 3,4,5-triCQA	Akt NF-κB	Inflammation/Immunology Cancer
3,4,5-Tricaffeoylquinic acid (3,4,5-triCQA) inhibits tumor necrosis factor-α-stimulated production of inflammatory mediators in keratinocytes via suppression of Akt- and NF-κB-pathways. 3,4,5-Tricaffeoylquinic acid induces cell cycle arrest at G0/G1, actin cytoskeleton organization, chromatin remodeling, neuronal differentiation, and bone morphogenetic protein signaling in human neural stem cells. 3,4,5-Tricaffeoylquinic acid has the potential for the research of aging-associated diseases .

HY-W778057

Ethyl 3,4-Dihydroxybenzoate-13C3 Protocatechuic acid ethyl ester-¹³C₃	Reactive Oxygen Species (ROS)	Cancer
Ethyl 3,4-Dihydroxybenzoate- ¹³C₃ (Protocatechuic acid ethyl ester- ¹³C₃) is the ¹³C-labeled Ethyl 3,4-dihydroxybenzoate (HY-W016409). Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

HY-W016409R

Ethyl 3,4-dihydroxybenzoate (Standard) Protocatechuic acid ethyl ester (Standard)	Reference Standards HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) NO Synthase Autophagy Apoptosis	Metabolic Disease Cancer
Ethyl 3,4-dihydroxybenzoate (Standard) (Protocatechuic acid ethyl ester (Standard)) is the analytical standard of Ethyl 3,4-dihydroxybenzoate (HY-W016409). This product is intended for research and analytical applications. Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of *hypoxia-inducible* factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α** by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

Cat. No.	Product Name

HY-L131

Osteogenesis Compound Library	726 compounds
Ossification is a tightly regulated process, performed by specialized cells called osteoblasts. Dysregulation of this process may cause inadequate or excessive mineralization of bones or ectopic calcification, all of which have grave consequences for human health. Osteoblasts play important roles in the process of osteogenesis and prevention of osteonecrosis. Osteoblast formation and bone formation are regulated by hormones, growth factors, cytokines, etc. MCE offers a unique collection of 726 bone formation compounds with identified and potential inducing osteogenesis activity. MCE bone formation compound library is a useful tool for the study of bone disease drugs and pharmacology.

Osteogenesis Compound Library

726 compounds

Ossification is a tightly regulated process, performed by specialized cells called osteoblasts. Dysregulation of this process may cause inadequate or excessive mineralization of bones or ectopic calcification, all of which have grave consequences for human health.

Osteoblasts play important roles in the process of osteogenesis and prevention of osteonecrosis. Osteoblast formation and bone formation are regulated by hormones, growth factors, cytokines, etc.

MCE offers a unique collection of 726 bone formation compounds with identified and potential inducing osteogenesis activity. MCE bone formation compound library is a useful tool for the study of bone disease drugs and pharmacology.

HY-L038

Differentiation Inducing Compound Library	2,039 compounds
Stem cells, which are found in all multi-cellular organisms, can divide and differentiate into diverse special cell types and can self-renew to produce more stem cells. To be useful in therapy, stem cells must be converted into desired cell types as necessary which is called induced differentiation or directed differentiation. Understanding and using signaling pathways for differentiation is an important method in successful regenerative medicine. Small molecules or growth factors induce the conversion of stem cells into appropriate progenitor cells, which will later give rise to the desired cell type. There is a variety of signal molecules and molecular families that may affect the establishment of germ layers in vivo, such as fibroblast growth factors (FGFs); the wnt family or superfamily of transforming growth factors β (TGFβ) and bone morphogenetic proteins (BMP). Unfortunately, for now, a high cost of recombinant factors is likely to limit their use on a larger scale in medicine. The more promising technique focuses on the use of small molecules. These small molecules can be used for either activating or deactivating specific signaling pathways. They enhance reprogramming efficiency by creating cells that are compatible with the desired type of tissue. It is a cheaper and non-immunogenic method. MCE Differentiation Inducing Compound Library contains a unique collection of 2,039 compounds that act on signaling pathways for differentiation. These compounds are potential stimulators for induced differentiation. This library is a useful tool for researching directed differentiation and regenerative medicine.

Differentiation Inducing Compound Library

2,039 compounds

Stem cells, which are found in all multi-cellular organisms, can divide and differentiate into diverse special cell types and can self-renew to produce more stem cells. To be useful in therapy, stem cells must be converted into desired cell types as necessary which is called induced differentiation or directed differentiation. Understanding and using signaling pathways for differentiation is an important method in successful regenerative medicine. Small molecules or growth factors induce the conversion of stem cells into appropriate progenitor cells, which will later give rise to the desired cell type. There is a variety of signal molecules and molecular families that may affect the establishment of germ layers in vivo, such as fibroblast growth factors (FGFs); the wnt family or superfamily of transforming growth factors β (TGFβ) and bone morphogenetic proteins (BMP). Unfortunately, for now, a high cost of recombinant factors is likely to limit their use on a larger scale in medicine. The more promising technique focuses on the use of small molecules. These small molecules can be used for either activating or deactivating specific signaling pathways. They enhance reprogramming efficiency by creating cells that are compatible with the desired type of tissue. It is a cheaper and non-immunogenic method.

MCE Differentiation Inducing Compound Library contains a unique collection of 2,039 compounds that act on signaling pathways for differentiation. These compounds are potential stimulators for induced differentiation. This library is a useful tool for researching directed differentiation and regenerative medicine.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-12316

20(S)-Hydroxycholesterol 2 Publications Verification 20α-Hydroxycholesterol	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Steroids Cancer	Smo Endogenous Metabolite
20(S)-Hydroxycholesterol (20α-Hydroxycholesterol) is an allosteric activator that selectively targets the Smoothened (Smo) of the Hedgehog pathway with an EC₅₀ of ~30 μM (Hedgehog). 20(S)-Hydroxycholesterol binds to the extracellular cysteine-rich domain (CRD) of Smo in a stereoselective manner, activating downstream Gli transcription factors (without inducing transcription of receptor genes in the Wnt pathway). 20(S)-Hydroxycholesterol enhances osteogenic differentiation of bone marrow stromal cells and synergistically activates the Raf/MEK/ERK pathway with Simvastatin (HY-17502) to promote bone regeneration. 20(S)-Hydroxycholesterol can be used to study the mechanisms of developmental biology, oncology, bone, and angiogenesis .

HY-W016409

Ethyl 3,4-dihydroxybenzoate 1 Publications Verification Protocatechuic acid ethyl ester	Structural Classification Arachis hypogaea L. Classification of Application Fields Leguminosae Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) NO Synthase Autophagy Apoptosis
Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of *hypoxia-inducible* factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α** by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

HY-128754

Monoolein 1 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite Interleukin Related TNF Receptor NO Synthase
Monoolein is a biocompatible lipid molecule that can be used as a carrier for bone repair. Monoolein exhibits anti-inflammatory activity by inhibiting the immune response induced by LPS (HY-D1056). It exerts its anti-inflammatory effects by reducing the production of immune response factors such as IL-12 p40, IL-6, and TNF-α, and inhibiting the generation of NO. Monoolein can be used in drug delivery and research in the field of inflammatory diseases .

HY-N6588

3,4,5-Tricaffeoylquinic acid 3,4,5-triCQA	Structural Classification Classification of Application Fields Simple Phenylpropanols Source classification Phenols Polyphenols Phenylpropanoids Plants Convolvulaceae Inflammation/Immunology Disease Research Fields Ipomoea batatas (Linn.) Lamarck	Akt NF-κB
3,4,5-Tricaffeoylquinic acid (3,4,5-triCQA) inhibits tumor necrosis factor-α-stimulated production of inflammatory mediators in keratinocytes via suppression of Akt- and NF-κB-pathways. 3,4,5-Tricaffeoylquinic acid induces cell cycle arrest at G0/G1, actin cytoskeleton organization, chromatin remodeling, neuronal differentiation, and bone morphogenetic protein signaling in human neural stem cells. 3,4,5-Tricaffeoylquinic acid has the potential for the research of aging-associated diseases .

HY-125393

Leustroducsin A	Structural Classification Natural Products Microorganisms Source classification	c-Fms
Leustroducsin A is a *colony-stimulating factor* (CSF)** inducer. Leustroducsin A induces production of CSF by bone marrowstromal cells .

HY-125377

Leustroducsin C	Structural Classification Natural Products Microorganisms Source classification	c-Fms
Leustroducsin C is a *colony-stimulating factor* (CSF)** inducer. Leustroducsin C induces production of CSF by bone marrowstromal cells .

HY-125086

Leustroducsin B LSN-B	Structural Classification Natural Products Microorganisms Source classification	c-Fms
Leustroducsin B is a *colony-stimulating factor* (CSF)** inducer. Leustroducsin B induces CSF production in bone marrow stromal cells .

HY-128754R

Monoolein (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite Interleukin Related TNF Receptor NO Synthase
Monoolein is a biocompatible lipid molecule that can be used as a carrier for bone repair. Monoolein exhibits anti-inflammatory activity by inhibiting the immune response induced by LPS (HY-D1056). It exerts its anti-inflammatory effects by reducing the production of immune response factors such as IL-12 p40, IL-6, and TNF-α, and inhibiting the generation of NO. Monoolein can be used in drug delivery and research in the field of inflammatory diseases .

HY-W016409R

Ethyl 3,4-dihydroxybenzoate (Standard) Protocatechuic acid ethyl ester (Standard)	Structural Classification Arachis hypogaea L. Leguminosae Source classification Phenols Polyphenols Plants	Reference Standards HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) NO Synthase Autophagy Apoptosis
Ethyl 3,4-dihydroxybenzoate (Standard) (Protocatechuic acid ethyl ester (Standard)) is the analytical standard of Ethyl 3,4-dihydroxybenzoate (HY-W016409). This product is intended for research and analytical applications. Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of *hypoxia-inducible* factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α** by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

Cat. No.	Product Name	Chemical Structure

HY-W778057

Ethyl 3,4-Dihydroxybenzoate-13C3
Ethyl 3,4-Dihydroxybenzoate- ¹³C₃ (Protocatechuic acid ethyl ester- ¹³C₃) is the ¹³C-labeled Ethyl 3,4-dihydroxybenzoate (HY-W016409). Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

Ethyl 3,4-Dihydroxybenzoate-13C3

Ethyl 3,4-Dihydroxybenzoate- ¹³C₃ (Protocatechuic acid ethyl ester- ¹³C₃) is the ¹³C-labeled Ethyl 3,4-dihydroxybenzoate (HY-W016409). Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

Cat. No.	Product Name		Classification

HY-128754

Monoolein 1 Publications Verification		Emulsifiers
Monoolein is a biocompatible lipid molecule that can be used as a carrier for bone repair. Monoolein exhibits anti-inflammatory activity by inhibiting the immune response induced by LPS (HY-D1056). It exerts its anti-inflammatory effects by reducing the production of immune response factors such as IL-12 p40, IL-6, and TNF-α, and inhibiting the generation of NO. Monoolein can be used in drug delivery and research in the field of inflammatory diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

bone inducible factors

Inhibitors & Agonists

Screening Libraries

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products